Ascletis Pharma has reported positive topline Phase III results showing that denifanstat (ASC40), a first-in-class oral FASN inhibitor for moderate-to-severe acne, delivered a favorable long-term ...
Clinical Trials Arena on MSN
Ascletis reports positive results in Phase III denifanstat trial for acne
Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.
Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.
Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...
Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...
Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...
The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...
The incidence of acne varies by transgender status, in a multicenter cohort study of transgender individuals starting hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results